Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 24, 2019 - Issue 3
Submit an article Journal homepage
429
Views
19
CrossRef citations to date
0
Altmetric
Review

Emerging protein kinase inhibitors for the treatment of multiple myeloma

Judith LindDepartment of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, AustriaView further author information
,
Felix CzernilofskyDepartment of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, AustriaView further author information
,
Sonia ValletDepartment of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, AustriaView further author information
&
Klaus PodarDepartment of Internal Medicine II, University Hospital Krems, Karl Landsteiner University of Health Sciences, Krems an der Donau, AustriaCorrespondence[email protected]
View further author information
Pages 133-152 | Received 05 May 2019, Accepted 19 Jul 2019, Published online: 29 Jul 2019

Citations (19)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Foteini Theodorakakou, Meletios A. Dimopoulos & Efstathios Kastritis. (2021) Mutation-dependent treatment approaches for patients with complex multiple myeloma. Expert Review of Precision Medicine and Drug Development 6:3, pages 189-201.
Read now

Articles from other publishers (18)

Mariaserena Giliberto, Leonardo Miranda Santana, Toril Holien, Kristine Misund, Sigve Nakken, Daniel Vodak, Eivind Hovig, Leonardo A. Meza-Zepeda, Eivind Coward, Anders Waage, Kjetil Taskén & Sigrid S. Skånland. (2022) Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines. Frontiers in Oncology 12.
Crossref
Igor Valentim Barreto, Caio Bezerra Machado, Davi Benevides Almeida, Flávia Melo Cunha de Pinho Pessoa, Renan Brito Gadelha, Laudreísa da Costa Pantoja, Deivide de Sousa Oliveira, Rodrigo Monteiro Ribeiro, Germison Silva Lopes, Manoel Odorico de Moraes Filho, Maria Elisabete Amaral de Moraes, André Salim Khayat, Edivaldo Herculano Correa de Oliveira & Caroline Aquino Moreira-Nunes. (2022) Kinase Inhibition in Multiple Myeloma: Current Scenario and Clinical Perspectives. Pharmaceutics 14:9, pages 1784.
Crossref
Shan-Liang Sun, Shi-Han Wu, Ji-Bo Kang, Yi-Yuan Ma, Lu Chen, Peng Cao, Liang Chang, Ning Ding, Xin Xue, Nian-Guang Li & Zhi-Hao Shi. (2022) Medicinal Chemistry Strategies for the Development of Bruton’s Tyrosine Kinase Inhibitors against Resistance. Journal of Medicinal Chemistry 65:11, pages 7415-7437.
Crossref
Pan Zhou, Mengyu Xiao, Weiya Li, Xiaobai Sun, Yanliang Bai, Feiying Meng, Zunmin Zhu, Weiping Yuan & Kai Sun. (2022) SHP2 Inhibitors Show Anti-Myeloma Activity and Synergize With Bortezomib in the Treatment of Multiple Myeloma. Frontiers in Pharmacology 13.
Crossref
Reiko Isa, Mano Horinaka, Taku Tsukamoto, Kentaro Mizuhara, Yuto Fujibayashi, Yoko Taminishi-Katsuragawa, Haruya Okamoto, Shusuke Yasuda, Yuka Kawaji-Kanayama, Yayoi Matsumura-Kimoto, Shinsuke Mizutani, Yuji Shimura, Masafumi Taniwaki, Toshiyuki Sakai & Junya Kuroda. (2022) The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. International Journal of Molecular Sciences 23:6, pages 2919.
Crossref
Anja Steinmaurer, Isabella Wimmer, Thomas Berger, Paulus S Rommer & Johann Sellner. (2022) Bruton's Tyrosine Kinase Inhibition in the Treatment of Preclinical Models and Multiple Sclerosis. Current Pharmaceutical Design 28:6, pages 437-444.
Crossref
Zhenzhen Zhang, Xin Liu, Liyun Zhao, Yaru Zhou, Jianyou Shi, Weini Chen & Jinqi Li. (2022) A review on the treatment of multiple myeloma with small molecular agents in the past five years. European Journal of Medicinal Chemistry 229, pages 114053.
Crossref
Rikio Suzuki, Yuka Kitamura, Daisuke Ogiya, Yoshiaki Ogawa, Hiroshi Kawada & Kiyoshi Ando. (2021) Anti-tumor activity of the pan-RAF inhibitor TAK-580 in combination with KPT-330 (selinexor) in multiple myeloma. International Journal of Hematology 115:2, pages 233-243.
Crossref
Emilie Logie, Claudina Perez Novo, Amber Driesen, Pieter Van Vlierberghe & Wim Vanden Berghe. (2021) Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells. International Journal of Molecular Sciences 22:23, pages 12731.
Crossref
Klaus Podar & Xavier Leleu. (2021) Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond. Cancers 13:20, pages 5154.
Crossref
Lukas John, Maria Theresa Krauth, Klaus Podar & Marc-Steffen Raab. (2021) Pathway-Directed Therapy in Multiple Myeloma. Cancers 13:7, pages 1668.
Crossref
Yang Cao, Huizhuang Shan, Meng Liu, Jia Liu, Zilu Zhang, Xiaoguang Xu, Yue Liu, Hanzhang Xu, Hu Lei, Miao Yu, Xingming Zhang, Wanting Liu, Zhilei Bu, Zhixiao Fang, Yanjie Ji, Hua Yan, Weiying Gu & Yingli Wu. (2021) Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib. Cell Death & Disease 12:4.
Crossref
Václav Němec, Lukáš Maier, Benedict-Tilman Berger, Apirat Chaikuad, Stanislav Drápela, Karel Souček, Stefan Knapp & Kamil Paruch. (2021) Highly selective inhibitors of protein kinases CLK and HIPK with the furo[3,2-b]pyridine core. European Journal of Medicinal Chemistry 215, pages 113299.
Crossref
Tina Paradzik, Cecilia Bandini, Elisabetta Mereu, Maria Labrador, Elisa Taiana, Nicola Amodio, Antonino Neri & Roberto Piva. (2021) The Landscape of Signaling Pathways and Proteasome Inhibitors Combinations in Multiple Myeloma. Cancers 13:6, pages 1235.
Crossref
Qi Liang, Juelan Wang, Liyun Zhao, Jun Hou, Yonghe Hu & Jianyou Shi. (2021) Recent advances of dual FGFR inhibitors as a novel therapy for cancer. European Journal of Medicinal Chemistry 214, pages 113205.
Crossref
Paula Martín Moyano, Václav Němec & Kamil Paruch. (2020) Cdc-Like Kinases (CLKs): Biology, Chemical Probes, and Therapeutic Potential. International Journal of Molecular Sciences 21:20, pages 7549.
Crossref
Xin-yang Li, Shuai Li, Guo-qing Lu, De-pu Wang, Kai-li Liu, Xin-hua Qian, Wen-han Xue & Fan-hao Meng. (2020) Design, synthesis and biological evaluation of novel (E)-N-phenyl-4-(pyridine-acylhydrazone) benzamide derivatives as potential antitumor agents for the treatment of multiple myeloma (MM). Bioorganic Chemistry 103, pages 104189.
Crossref
Meral Beksac, Sevinc Balli & Dilara Akcora Yildiz. (2020) Drug Targeting of Genomic Instability in Multiple Myeloma. Frontiers in Genetics 11.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.